Nicotine consumption in the United States is changing rapidly. Traditional cigarette smoking continues to decline, while alternative nicotine products such as e-cigarettes, heated tobacco, and oral nicotine pouches are gaining attention. One product now at the center of a national regulatory discussion is Zyn, a flavored nicotine pouch manufactured by Philip Morris International.
In January 2026, the U.S. Food and Drug Administration held a public meeting to evaluate whether Zyn could be marketed as a lower-risk nicotine option for adults who currently smoke cigarettes. If approved, this decision could significantly affect how nicotine products are labeled, advertised, and perceived by the public.
This article explains what Zyn is, why the FDA is reviewing it, what the scientific evidence suggests, and the public health concerns surrounding its growing popularity.
Zyn is a smokeless, tobacco-free nicotine pouch designed to be placed between the upper lip and gum. Unlike cigarettes, cigars, or chewing tobacco, Zyn does not involve combustion or inhalation. Instead, nicotine is absorbed through the oral lining.
Zyn pouches contain nicotine powder, flavorings, sweeteners, and plant-based fillers. They are sold in several nicotine strengths and a variety of flavors, including mint, citrus, and coffee. Because there is no burning or smoke, users are not exposed to tar or many of the toxic byproducts associated with cigarette smoking.
Zyn received FDA authorization in early 2025 to remain on the U.S. market after an extensive review process. At that time, regulators concluded that the product appeared to pose fewer health risks than traditional cigarettes.
Philip Morris International is now seeking permission to market Zyn as a reduced-risk alternative to cigarettes for adults who already smoke. This type of request falls under the FDA’s Modified Risk Tobacco Product framework, which allows companies to make health-related claims only if they are supported by scientific evidence and do not harm public health overall.
The company wants approval to state that switching completely from cigarettes to Zyn may lower the risk of serious smoking-related diseases such as:
According to FDA documents released ahead of the January 2026 meeting, agency scientists believe these claims may be scientifically accurate, though a final decision has not yet been made.
One of the strongest arguments in favor of Zyn is that it does not involve burning tobacco. Combustion produces thousands of harmful chemicals, including dozens known to cause cancer. Eliminating smoke exposure significantly reduces health risks.
Company testing submitted to the FDA showed that 36 out of 42 known carcinogenic compounds commonly found in tobacco products were either not detected in Zyn or present at extremely low levels. For the remaining six chemicals, FDA reviewers reported that concentrations were below levels expected to cause harm.
Because Zyn is relatively new, long-term health studies are not yet available. Instead, Philip Morris relied on extensive research from Sweden involving snus, a smokeless oral tobacco product that has been widely used for decades.
Multiple Scandinavian studies have found that snus users experience significantly lower rates of lung cancer and oral cancer compared with cigarette smokers. FDA scientists noted that Zyn may carry even fewer risks than snus because it contains nicotine but no tobacco leaf material.
Although nicotine pouches are still used by fewer than 1 percent of U.S. adults, they represent the fastest-growing category in the nicotine market. Cigarette use continues to decline as people quit smoking, switch to alternatives, or die from smoking-related illnesses.
Zyn currently dominates the U.S. nicotine pouch market. According to a Goldman Sachs analysis, the brand generated $3.24 billion in sales last year, accounting for more than two-thirds of total pouch sales nationwide.
Philip Morris reports that most Zyn users are adults in their 30s and 40s, and that they generally have higher incomes than traditional cigarette smokers or e-cigarette users.
While the FDA considers allowing reduced-risk marketing claims, regulators must also evaluate whether such messaging could unintentionally increase nicotine use among young people or non-smokers.
Zyn has gained visibility on platforms like TikTok and Instagram, where influencers sometimes referred to as “Zynfluencers” post videos that collectively have received tens of millions of views. These videos often portray Zyn as trendy, discreet, or socially acceptable.
A study by the nonprofit Truth Initiative found that spikes in viral Zyn content during 2022 and 2023 were followed by increases in sales. However, researchers cautioned that the data did not prove a direct cause-and-effect relationship.
Despite these concerns, recent federal survey data show that teen use remains relatively low. About 2.4 percent of U.S. high school students reported using nicotine pouches, which is significantly lower than historical rates of youth cigarette smoking or vaping.
The FDA must weigh whether allowing reduced-risk claims would help adult smokers quit cigarettes without increasing nicotine initiation among young people.
If the FDA grants Philip Morris permission to market Zyn as a lower-risk product, the company would be allowed to use specific language in advertising directed at adults who already use tobacco products.
This would not mean that Zyn is considered safe or harmless. Instead, it would acknowledge that switching completely from cigarettes to Zyn is likely less dangerous than continuing to smoke.
Importantly, any approval would likely come with strict conditions on marketing, labeling, and audience targeting to minimize youth exposure.
Public health experts remain divided on nicotine harm reduction. Some argue that encouraging smokers to switch to less harmful alternatives could prevent millions of deaths over time. Others worry that promoting nicotine products in any form could normalize addiction and undermine decades of anti-smoking efforts.
The FDA’s ongoing review of Zyn reflects this tension. The agency has no fixed deadline for a final decision, and outside health experts will continue to provide input before a ruling is issued.
The FDA’s review of Zyn nicotine pouches represents a critical moment in U.S. tobacco regulation. Scientific evidence suggests that Zyn exposes users to far fewer harmful chemicals than cigarettes, and switching completely may reduce the risk of serious smoking-related diseases for adults who already smoke.
At the same time, regulators must carefully consider how marketing claims could influence youth behavior and public perception of nicotine use. The final decision will likely shape the future of reduced-risk nicotine products in the United States.
As cigarette smoking continues to decline, products like Zyn may play a growing role in how society approaches nicotine, addiction, and harm reduction.
This article is for informational and educational purposes only and does not constitute medical advice, diagnosis, or treatment. Statistical data reflects general population trends and may not apply to individual circumstances. Nicotine is an addictive substance and may pose health risks. Always consult a qualified healthcare professional for personalized medical guidance and smoking cessation advice.
Most Accurate Healthcare AI designed for everything from admin workflows to clinical decision support.